ONE-WAYOngoing theme · still written in the latest filings

Development of the infectious disease POCT and OTC testing business

The company plans to develop genetic point-of-care testing (POCT) instruments and reagents for infectious diseases, as well as over-the-counter (OTC) tests for self-care, into core businesses and expand the testing market for healthcare institutions, private-practice physicians and individuals.

Companies2How many companies write about this.

Threads3One company can carry more than one thread here.

PeriodFY2016 →Still being written about.

Directionhelps3 helps · 0 hurts · 0 flat